Table 4.
Incidence of Adverse Drug Reactions During Treatment Among Pediatric Patients Treated for Multidrug-Resistant Tuberculosis in the Country of Georgia, 2009–2016 (N = 119)
| Adverse Events | Total |
|---|---|
| N = 119 N (%) | |
| Any adverse events | 94 (79.0) |
| Hypokalemiaa | 14 (11.8) |
| Nausea | 64 (53.9) |
| Rashes | 18 (15.1) |
| Joint pain (arthralgia) | 29 (24.4) |
| Gastrointestinal tract disturbance | 22 (18.5) |
| Headache | 12 (10.1) |
| Anxiety | 22 (18.5) |
| Optic neuritis | 1 (0.8) |
| Hearing loss | 3 (2.5) |
| Renal failureb | 1 (0.8) |
| Peripheral neuropathy | 4 (3.4) |
| Elevated liver enzymesc | 4 (3.4) |
| Anemiad | 1 (0.8) |
| Itchiness | 1 (0.8) |
| Seizure | 5 (4.2) |
| Thrombocytopeniae | 2 (1.7) |
aHypokalemia was defined when the potassium level (K+) is less than 3.3 mmol/dL.
bRenal failure was defined according to doctor’s note in the medical chart.
cElevated liver enzymes were defined if patients had elevated alanine transaminase (ALT) (ie, ALT > 37 U/L) or elevated aspartate transaminase (AST) (ie, AST > 42 U/L).
dAnemia was defined by the hemoglobin age-specific cutoff following the Georgian guideline.
eThrombocytopenia was defined when the platelet count is less than 140 × 109/L.